Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

A recent paper by Marchiò and colleagues indicated that true polysomy of chromosome 17 is rare and that coincident CEP 17 centromere amplification may account for its overestimation in FISH testing for HER2 amplification, with a treat/not treat decision as the final important readout. Here the importance of relating HER2 copy number to cell count rather than a ratio with CEP17 is emphasized. This is central to ensuring that all who may respond to potentially life-saving treatment with herceptin/lapatininib are not denied these drugs.

Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalJournal of Pathology
Volume219
Issue number1
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Chromosomes, Human, Pair 17
Centromere
Cell Count
Breast Neoplasms
Pharmaceutical Preparations
Trastuzumab

Keywords

  • Amplification
  • CEP17
  • erbB2
  • HER2
  • Herceptin
  • Polysomy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. / Viale, Giuseppe.

In: Journal of Pathology, Vol. 219, No. 1, 09.2009, p. 1-2.

Research output: Contribution to journalArticle

@article{68c3c4a54fb145faa3035d194ee23d64,
title = "Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer",
abstract = "A recent paper by Marchi{\`o} and colleagues indicated that true polysomy of chromosome 17 is rare and that coincident CEP 17 centromere amplification may account for its overestimation in FISH testing for HER2 amplification, with a treat/not treat decision as the final important readout. Here the importance of relating HER2 copy number to cell count rather than a ratio with CEP17 is emphasized. This is central to ensuring that all who may respond to potentially life-saving treatment with herceptin/lapatininib are not denied these drugs.",
keywords = "Amplification, CEP17, erbB2, HER2, Herceptin, Polysomy",
author = "Giuseppe Viale",
year = "2009",
month = "9",
doi = "10.1002/path.2593",
language = "English",
volume = "219",
pages = "1--2",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer

AU - Viale, Giuseppe

PY - 2009/9

Y1 - 2009/9

N2 - A recent paper by Marchiò and colleagues indicated that true polysomy of chromosome 17 is rare and that coincident CEP 17 centromere amplification may account for its overestimation in FISH testing for HER2 amplification, with a treat/not treat decision as the final important readout. Here the importance of relating HER2 copy number to cell count rather than a ratio with CEP17 is emphasized. This is central to ensuring that all who may respond to potentially life-saving treatment with herceptin/lapatininib are not denied these drugs.

AB - A recent paper by Marchiò and colleagues indicated that true polysomy of chromosome 17 is rare and that coincident CEP 17 centromere amplification may account for its overestimation in FISH testing for HER2 amplification, with a treat/not treat decision as the final important readout. Here the importance of relating HER2 copy number to cell count rather than a ratio with CEP17 is emphasized. This is central to ensuring that all who may respond to potentially life-saving treatment with herceptin/lapatininib are not denied these drugs.

KW - Amplification

KW - CEP17

KW - erbB2

KW - HER2

KW - Herceptin

KW - Polysomy

UR - http://www.scopus.com/inward/record.url?scp=68849119063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849119063&partnerID=8YFLogxK

U2 - 10.1002/path.2593

DO - 10.1002/path.2593

M3 - Article

VL - 219

SP - 1

EP - 2

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 1

ER -